Pages

Look Towards A New Future

Sep 19, 2012

Metabolic Partnering Terms and Agreements

This report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter metabolic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors metabolic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

Get a copy of this report @ http://www.reportsnreports.com/reports/191581-metabolic-partnering-terms-and-agreements.html

Report Details:

Published: September 2012
No. of Pages: 448
Price:Single User License:US$2695 Corporate User License:US$13475



This report contains over 1,000 links to online copies of actual metabolic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in metabolic dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading metabolic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of metabolic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all metabolic deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all metabolic partnering deals signed and announced since 2007. The chapter is organized by specific metabolic therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all metabolic partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in metabolic partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of metabolic technologies and products.

Metabolic Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of metabolic deal trends since 2007
Access metabolic deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between metabolic partner companies
Comprehensive access to over 1,000 links to actual metabolic deals entered into by the world’s biopharma companies
Indepth review of metabolic deals entered into by the leading fifty bigpharma companies
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner metabolic opportunities
Uncover companies actively partnering metabolic opportunities

Analysis of Blood Typing, Grouping and Screening Tests, and Strategic Profiles of Leading Suppliers

This report presents a comprehensive analysis of the clinical significance and market needs for major blood typing, grouping, and infectious disease screening assays, including NAT tests, as well as extensive listings of companies developing or marketing new blood banking technologies and products.

Get your copy of this report @ http://www.reportsnreports.com/reports/193930-analysis-of-blood-typing-grouping-and-screening-tests-and-strategic-profiles-of-leading-suppliers.html

Report Details:

Published: September 2012
No. of Pages: 255
Price:Single User License:US$3500 Corporate User License:US$7500



Table Of Contents

1.Blood Typing and Grouping Tests
a.ABO
b.Antibody Panels
c.Antibody Screening
d.Antigen Typing
e.Antiglobulin Test
f.Crossmatch
g.HLA Typing
h.Rh
i.Other Blood Groups

2.Infectious Disease Screening Tests
a.AIDS
Structure and Composition
Classification
Origin of AIDS
Animal Lentivirus Systems
Virus Receptors
HIV Infections in Humans
Pathogenesis & Pathology
Overview of Course of HIV Infection
CD4T Lymphocytes and Memory Cells
Monocytes and Macrophages
Lymphoid Organs
Neural Cells
Viral Coinfections
Clinical Findings
Plasma Viral Load
Pediactric AIDS
Neurologic Disease
Opportunistic Infections
Protozoa
Fungi
Bacteria
Viruses
Cancer
Immunity
Laboratory Diagnosis
Virus Isolation
Serology
Detection of Viral Nucleic Acid or Antigens
Epidemiology
Worldwide Spread of AIDS
United States
Routes of Transmission
Prevention, Treatment, And Control
Antiviral Drugs
Vaccines Against HIV
Transmission of HIV in Blood Products
HIV Transmission in Transplant and
Artificial Insemination Recipients
Diagnostic Tests
Enzyme Immunoassay Interpretation
Specificity, Sensitivity, and Predictive
Value of Enzyme Immunoassay
Competition Assays
Western Blot Technique
ImmunoFluorescence Assay (IFA)
Radioimmunoprecipitation
HIV1/HIV2 Combination Testing
Methods of HIVAntigen Detection
Antigen Assays and Blood Screening
Urine Tests
DNA Probes
Overview
Quantitative Polymerase Chain Reaction
In Situ PCR
Needed Improvements
Viral Load/Drug Resistance Testing
Genotype and Phenotype Testing
Blood Banking Considerations
b.Hepatitis
Hepatitis A
Hepatitis B
Structure and Composition
Replication of Hepatitis B Virus
Hepatitis C
Hepatitis D (Delta Hepatitis)
Hepatitis E
Hepatitis G
Hepatitis Virus Infections In Humans
Pathology
Clinical Findings
Laboratory Features
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
VirusHost Immune Reactions
Epidemiology
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D (Delta Agent)
Vaccines and Drugs
c.Cytomegalovirus
Background
Chorioretinitis
Gastrointestinal
Central Nervous System Disease
Diagnostic Tests
Vaccines and Drugs
d.Syphilis
Background
Diagnostic Tests
Vaccines and Drugs
e.West Nile Virus
Background
Clinical Syndromes
Diagnostic Tests
Vaccines and Drugs
f.Parvovirus B19
Microbiology
Epidemiology
Clinical Syndromes
Erythema Infectiosum Slapped (cheek)
Adult Polyarthropathy
Transient Aplastic Crisis
Transient Pancytopenia
Red Cell Aplasia in the Immunocompromised
Perinatal Infections
Diagnosis
Treatment
g. CreutzfeldtJakob’s Disease
Background
Transmission
Diagnostic Tests
Major Commercial and Academic Players
Bayer
Disease Sciences/BioTec Global
Imperial College School of Medicine
OrthoClinical Diagnostics
Pall
ProMetic Life Sciences
Proteome Sciences/Idexx
QOne Biotech
Serono
U.S. Agricultural Research Service
Drugs
Vaccines
h.Malaria
i.Chagas Disease
j.Babesiosis

3.Pathogen Reduction

4.Leukocyte Reduction
Background
Methods
Competitive Assessments
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Biokit
BioMerieux
BioRad
Diagast
DiaSorin
Fujirebio
GenProbe
Grifols
Immucor
Innogenetics
OrthoClinical Diagnostics
Orchid CellMark
Novartis Diagnostics
Proteome Sciences
Roche
Siemens
Tecan

List of Tables

Major Companies Developing or Marketing
Blood Typing and Grouping Tests
Major Companies Developing or Marketing
HLA Typing Tests
Major Companies Developing or Marketing
AIDS Tests
Major Companies Developing or Marketing
Hepatitis Tests
Major Companies Developing or Marketing
CMV Tests
Major Companies Developing or Marketing
Syphilis Tests

Gynecology Partnering Terms and Agreements

This report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gynecology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gynecology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual gynecology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Get your copy of this report @ http://www.reportsnreports.com/reports/191587-gynecology-partnering-terms-and-agreements.html

Report Details:

Published: September 2012
No. of Pages: 351
Price:Single User License:US$2695 Corporate User License:US$13475



The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gynecology dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading gynecology deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of gynecology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all gynecology deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all gynecology partnering deals signed and announced since 2007. The chapter is organized by specific gynecology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all gynecology partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in gynecology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gynecology technologies and products.

Gynecology Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of gynecology deal trends since 2007
Access gynecology deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between gynecology partner companies
Comprehensive access to over 500 links to actual gynecology deals entered into by the world’s biopharma companies
Indepth review of gynecology deals entered into by the leading fifty bigpharma companies
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner gynecology opportunities
Uncover companies actively partnering gynecology opportunities

Analysis of Emerging Cancer Diagnostic Tests and Strategic Profile of Leading Suppliers

This report presents comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.

Buy a copy of this report @ http://www.reportsnreports.com/reports/193931-analysis-of-emerging-cancer-diagnostic-tests-and-strategic-profile-of-leading-suppliers.html

Report Details:

Published: September 2012
No. of Pages: 286 
Price:Single User License:US$3500 Corporate User License:US$7500
 

Table of Contents

Major Current And Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers
ADA
B-Protein
PNP
5'-Nucleotidase

27. Oncogenes
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src

28. Polypeptide Growth Factors
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA 50
CA 72-4/TAG-72
CA 195
CA-242
CA-549
CAM 26
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA 93
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma 552
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor 1
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL 175
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG 12
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
Competitive Profiles
Abbott
AdnaGen
Applied Gene Technologies
Arca
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
Cepheid
Correlogic Systems
Dako
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Gen-Probe
Guided Therapeutics
Hologic
Ipsogen
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

Appendixes

Appendix I: Major Universities and Research
Centers Developing Cancer Diagnostic
Technology and Applications

Sexual Health Partnering Terms and Agreements

This report provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter sexual health partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors sexual health technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual sexual health deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Get a copy of this report @ http://www.reportsnreports.com/reports/191589-sexual-health-partnering-terms-and-agreements.html

Report Details:

Published: September 2012
No. of Pages: 595
Price:Single User License:US$1995 Corporate user License:US$9975



The initial chapters of this report provide an orientation of sexual health dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in sexual health dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading sexual health deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of sexual health deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all sexual health deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all sexual health partnering deals signed and announced since 2007. The chapter is organized by specific sexual health therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all sexual health partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in sexual health partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of sexual health technologies and products.

Sexual Health Partnering Terms and Agreements provides the reader with the following key benefits:
  • In-depth understanding of sexual health deal trends since 2007
  • Access sexual health deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between sexual health partner companies
  • Comprehensive access to over 500 links to actual sexual health deals entered into by the world’s biopharma companies
  • Indepth review of sexual health deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals 
  • Identify key terms under which companies partner sexual health opportunities
  • Uncover companies actively partnering sexual health opportunities

Sep 18, 2012

China Report | China Beer Market Insights 2012


 In 2011, the China beer market saw a steady growth of over 7%, which is a further 1% higher than the growth rate seen in 2010. The total consumption reached almost 498 m hl and maintained its top position in the world. Although economic growth does not have a big impact on the beer market, the lower economic growth forecast for 2012 will influence the income and consumption of particularly those on lower incomes. This will impact the low end and mainstream beer consumption to some extent. Therefore the 2012 forecast for beer market growth is around 5%, whilst the next three-year forecast is 3-5%.

During 2011, China faced a high and rising CPI that forced many brewers to raise retail prices. In January
2011, China Resources Snow Brewery Co Ltd (CRSB) increased its product prices by more than 10% in several provinces. A few months later, Tsingtao Brewery Co Ltd followed suit, raising the prices of several of its products by an average of 10%.

Given the country’s preference for high strength baijiu, health and safety issues associated with alcohol are a concern. In the last ten years, China’s alcohol consumption patterns have changed dramatically, from strong demand for the highly potent baijiu to the increased popularity of low or no alcohol beer.





The large breweries performed well in 2011; China Resources Snow Brewery Co Ltd (CRSB), Tsingtao and Yanjing all grew above the industry growth of 7% with growths of 11%, 9% and 10% respectively. There has also been further industry consolidation, with the top five brewers increasing volume share by 3% in 2011.

More local brewers are entering the premium segment and the trend for major Chinese breweries is to push
into the premium beer market.This is a market dominated by western brands such as Carlsberg and Heineken, accounting for 70% of sales in this segment. Chinese brands like Tsingtao already have the infrastructure, capital, distribution networks and international reach to branch into the premium segment.
Developing a high quality, premium product is a challenge and to convince Chinese drinkers to pay a premium over the price of locally produced beer, is a greater challenge.

About Canadean
Canadean has long held a reputation with FMCG markets for providing specialist business information by conducting detailed industry and consumer research, supported by insightful value-added analysis. We cover the entire spectrum of the consumer value chain from suppliers, brand owners, distribution channels and consumer insight.
By researching markets in a holistic way, Canadean’s research methodology enables clients to make informed strategical decisions that are founded on robust and reliable data and market insights. We specialize in online survey panels, qualitative and quantitative in-country research, industry analysis and consultancy.
Canadean’s dedicated in-country researchers and analysts have an industry background in marketing, market research, consulting and advanced statistical expertise. They are well positioned in the industries themselves and therefore, best placed to ask the right questions of the right people. This network of professional researchers stretches across more than 80 countries, enabling Canadean to conduct unique research via our trusted business communities. 

Get your copy of this report @ http://www.reportsnreports.com/reports/191941-china-beer-market-insights-2012.html

Report Details:
Published: September 2012
No. of Pages: 188
Price:US$12896




Sep 17, 2012

Market Report on Global Epoxy Resin Market By Application & Geography – Forecasts up to 2017

Epoxy resins are thermosetting resins known for its excellent mechanical, electrical and high heat resistance properties. Epoxy resins are also available in a wide variety of curing-agent variations. These are widely used in coating process, electronic applications, wind blades in windmill turbines, construction works, and adhesives, etc. Paints and coatings are primary application in terms of utilization of epoxy resins. Epoxy resins market growth is bound with the developing economies due to its high co-relation with industrialization.

This study estimates the global market of epoxy resins by the end of 2017. This market research study provides detailed qualitative and quantitative analysis of the global epoxy resins market. The report provides a comprehensive review of major market drivers, restraints, opportunities, winning imperatives, challenges, and key issues in the market. The market is further segmented and forecasted for major geographic regions such as: North America, Europe, Asia–Pacific, and Rest of the World that include key growth regions like China and India. Major countries with the market volumes and revenues are covered for each of the region. Competitive scenario and market share of the top players in the market has been discussed in detail. The top players of the industry are profiled in detail with their recent developments and other strategic industry activities.

Get your copy of this report @ http://www.reportsnreports.com/reports/192074-global-epoxy-resin-market-by-application-geography-forecasts-up-to-2017.html

Market has also been segmented on the basis of applications. The major applications for epoxy resins such as paints and coating, electrical and electronics, construction, wind turbine, adhesive, etc. have been discussed in detail in the report. Market share for major market participants has been described in detail for epoxy resins.

We have used various secondary sources such as encyclopedia, directories, company news flows, ministry reports, and databases to identify and collect information useful for this extensive commercial study. The primary sources – experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess the future prospects of epoxy resins.

We have also profiled leading players of this industry with their recent developments and other strategic industry activities. Key participants in the global epoxy resins market include The Dow Chemical Company (U.S.), Huntsman Corporation (U.S.), Kukdo Chemical (South Korea), Momentive Performance Materials Holdings LLC (U.S.), Nan Ya Plastics Corporation (Taiwan), NAMA Chemicals (Saudi Arabia), LEUNA-Harze GmbH (Germany), Spolchemie A.S. (Czech Republic), Aditya Birla Chemicals (Thailand) Ltd, BASF SE (Germany), 3M (U.S.), DuPont (U.S.), Cytec Industries Incorporation (U.S.), Sika AG (Switzerland), Atul Ltd (India), etc.

Scope of the report:
This epoxy resins market research report categorizes the global market for on the basis of applications and geography; forecasting volumes and revenues and analyzing trends in each of the submarkets.

On the basis of applications:
The epoxy resins market is segmented on the basis of industry application as paints and coating, construction, electronic, wind energy, adhesive, etc. Each application is further described in detail in the report with volumes and revenues forecasted for each application.

On the basis of geography:
North America, Europe, Asia-Pacific, and ROW and key countries in every region.

Report Details:
Published: September 2012
No. of Pages: 96
Price:Single User License:US$4650 Corporate User License:US$7150

Asthma Market and Product Forecasts


The asthma market has seen strong growth, with increased uptake of relatively expensive combination products. This trend is expected to change in the near future as sales growth will slow, and even turn negative, as key products face generic entry. However, by 2021, Datamonitor forecasts a return to positive growth such that the market will maintain value, with a CAGR over 2012–21 of 0.1%.
Features and benefits
  • Access Datamonitor’s patient-based asthma market forecast for the seven major markets, with transparent methodology and clear assumptions.
  • Understand how market dynamics are changing and which drug classes will be most impacted in the next 10 years.
  • Gain insight into how late-stage pipeline products will change the market and which currently marketed products are insulated against brand erosion.
  • See how generics will impact the asthma market and gain insight into which drug classes are the most vulnerable.
Highlights
Datamonitor forecasts four new product launches in asthma over the next 10 years. New products for asthma across the seven major markets will counteract generic erosion and help the market to maintain value. Datamonitor forecasts the asthma market to increase from $15.0bn in 2012 to $15.1bn by 2021, representing a 2012–21 CAGR of 0.1%.
The impact of generics will vary considerably by drug class. The antileukotriene class is expected to see a rapid decline as Singulair succumbs to generic entry. However, Datamonitor expects a relatively low impact of generics on inhaled combination products, although price discounting and patient switching will vary by country.
While the ICS/LABA class will remain unrivalled as the most profitable in asthma, it will see significant changes. The first ICS/LABA generics are expected to enter the market from 2013. However, greater patient switching is expected from current market leaders to the first once-daily ICS/LABAs, than to generics.
Your key questions answered
  • How can generics compete with new product launches in the ICS/LABA class?
  • How will current market leaders be impacted by additional product launches and which products will resist brand erosion?
  • How are class dynamics changing in asthma and which drug classes will be the most profitable in 2021?
  • How do asthma markets differ across the seven major markets and how will these markets react to events over the next 10 years? 

Construction Report | World Housing to 2016

World housing demand to increase 3.5% annually through 2016
Demand for housing is projected to spur the construction of 60.4 new housing units in 2016, an increase of 3.5 percent per annum. The strongest annual growth in construction will be in industrialized countries that had depressed housing markets in 2011. For most of these countries, the impressive growth rates will still leave the 2016 level of construction below that of a decade earlier, prior to the global financial crisis and resulting recession. In the US, for example, new housing construction will advance 18 percent per year to 1.5 million units in 2016, although that represents only 70 percent of the construction activity in 2006. Western Europe will also experience robust growth in new housing construction over the forecast period, rising 6.3 percent per annum to 1.8 million units.

China, Africa/Mideast to generate most new units
Housing construction in developing regions generally felt less of an impact from the global economic downturn in 2009 (with the notable exception of some markets in the Arabian peninsula), so growth through 2016 will be less fevered than in many industrialized countries. Ongoing rural-to-urban migration and  increases in the number of households will underpin demand for new housing units in developing regions through 2016.  Both the Africa/Mideast region and China will enjoy solid yearly gains. In the aggregate, those countries will generate 56 percent of the increase in construction of new housing units.

Multifamily housing to outpace single-family units
Multifamily housing units will record faster gains in new construction through 2016 than will single-family units. Increasing urbanization in developing countries will contribute to the trend. In the Africa/Mideast region, for instance, multifamily housing unit construction will accelerate to 4.4 percent per year through 2016. In that region and worldwide, however, single-family housing units will continue to constitute a majority of new housing construction.

World housing stock to increase 1.8% annually
The world housing stock was approaching two billion units in 2011, roughly one percent larger than the number of households. The Asia/Pacific region had the largest housing stock, with its nearly one billion units accounting for 51 percent of the world total; China alone represented 21 percent of the world total. The Africa/ Mideast region had the second largest housing stock in 2011, with 313 million units, or 16 percent of the world total. In the aggregate, Western Europe and North America together accounted for just under one-fifth of the housing stock.

The world stock of housing is expected to increase 1.8 percent per annum through 2016 to 2.1 billion units, a deceleration from the 2001-2011 period as new household formation slows. The most rapid increases in the housing stock will be in the Africa/Mideast region, fueled by above-average population growth. Gains will be driven both by new household formation and by efforts to expand the availability of housing for families who currently share space in one house. Increases in the housing stock in Central and South America will also surpass the world average, expanding 1.9 percent annually through 2016 to 155 million units. The Asia/Pacific region will retain its position as the leader in housing stock at 1.1 billion units, despite a deceleration in housing construction in China. 


Get your copy of this report @ http://www.reportsnreports.com/reports/192510-world-housing-to-2016.html
Report Details:
Published: September 2012
No. of Pages: 208
Price:US$5500        




Renewable Energy Market in South and Central America to 2020

GBI Research, a leading business intelligence provider, has released its latest research, “Renewable Energy Market in South and Central America to 2020 - Clean Development Mechanism Projects and Climate Financing to Increase Renewables Share in the Energy Mix”. The report gives an in-depth analysis of renewable power markets in south and central America, covering the five most prominent countries: Mexico, Brazil, Argentina, Chile and Colombia. The report covers the cumulative installed capacity and power generation of renewable technologies including small hydro, solar photovoltaic (PV), geothermal power, wind power and biomass between 2005 and 2020. The report also provides the market drivers and restraints for the renewable power market in the region. Lists of the foremost active and upcoming power plants for renewable power and technologies in each country are also provided in the report.

Scope
  • Analysis of the south and central America renewable power market covering Mexico, Brazil, Argentina, Chile and Colombia
  • Historical and forecast data on installed capacity and power generation for renewable technologies such as small hydro, solar PV, wind power, geothermal and biomass between 2005 and 2020
  • Market dynamics including drivers and restraints for the region
  • Prominent active and upcoming renewable power plants for renewable technologies for each of the countries covered
  • Renewable energy regulatory framework and policies overview for each country
Reasons to buy
  • Make strategic decisions based on strong historical and forecast data to identify key markets and growth opportunities for the south and central America renewable power markets
  • Understand the impact of renewable energy regulations and government policies to device market entry plans
  • The upcoming power projects in each country will help to analyze strategic locations for business expansion and will help manufacturers and suppliers in prospect identification
  • Evaluate potential of emerging markets to quantify return on investments 
Get a copy of this report @ http://www.reportsnreports.com/reports/192513-renewable-energy-market-in-south-and-central-america-to-2020-clean-development-mechanism-projects-and-climate-financing-to-increase-renewables-share-in-the-energy-mix.html

Report Details:

Published: September 2012
No. of Pages: 177
Price:Single User License:US$3500 Corporate User License:US$10500







Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market

GBI Research’s new report, “Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market”, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied various hurdles at different stages of drug development that can halt a drug’s development. The report provides detailed information about the need for accelerated drug development. Declining R&D productivity is highlighted as one of the major needs to be addressed. The report outlines misconceptions regarding accelerated drug development; one such major misconception is the cost of development. The cost of an accelerated development program can be effectively managed by implementing a structured and complete program. The report highlights major strategies adopted by pharmaceutical companies to accelerate drug development. The adoption of the latest technologies in lead generation, preclinical stages, and the use of adaptive designs in late phase studies are regarded as tools to accelerate drugs through these stages of development.

Buy a copy of this report @ http://www.reportsnreports.com/reports/192514-accelerating-drugs-to-market-despite-challenges-adaptive-clinical-trials-reduce-drug-development-costs-and-time-to-market.html

Report Details:

Published: September 2012
No. of Pages: 63
Price:Single User License:US$3500 Corporate User License:US$10500



The process of drug development starts from the initial discovery and ends with a final medication. This is an expensive, lengthy and incremental process. The main objective of the process is to identify a molecule with the potential for producing the desired effect in the human body, and to establish the quality, safety and efficacy of the molecule for treating patients. In the present scenario drug development takes about 12 years, for a molecule to progress from the laboratory and enter the pharmaceutical market. It is estimated that out of 5,000 compounds which enter the preclinical stage of development, only five compounds will be successful enough to be tested on humans, and only one among them will be approved. The slow pace of drug development greatly affects the pharmaceutical industry and patients who are in need of new therapeutics to treat their illness.

The current process of drug development begins with the synthesis of molecules, which targets specific proteins in living cells. It is followed by in vitro tests to identify any specific toxicity associated with the synthesized molecules. The compounds which make it through this stage will go further and will be tested for in vivo toxicology studies. The information gathered from these studies is utilized for planning and conducting clinical trials in human subjects.

It is important for biopharmaceutical companies to launch their products more quickly in the market, as this will lead to early revenue generation from the product. As a large number of drugs fail at the later stages of drug development, pharmaceutical companies try to maintain their revenues by launching new drugs at the earliest possible time. The decline in the total number of new drug approvals by the regulatory bodies and the patent expirations for major blockbuster drugs are forcing pharmaceutical companies to consider ways in which the time and cost of clinical trials can be reduced without affecting their quality.

Scope
  • The report presents various tools and strategies which can help to accelerate a drug to market.
  • The report provides detailed information about the need for accelerated drug development.
  • The report outlines misconceptions regarding accelerated drug development.
  • The report provides information on trends in drug transition and strategies and models adopted to accelerate drug transition through the various stages of development.
  • Description of the methods for optimum patient recruitment and retention in a clinical trial.
  • Analysis of efficient clinical trial site management so that completion of a trial is done on time.
Reasons to buy
  • Develop strategies to implement the use of various technologies for advancing drug discovery and development in an efficient manner.
  • Understand the use of biomarkers and surrogate endpoints, improvised clinical trial designs and better recruitment and retention of subjects in clinical trials, in order to avoid drug lags in various phases of development.
  • Prioritize design elements of study protocols and balance the overall protocol.
  • Ensure efficient clinical trial outcomes by implementing CDISC standards.
  • Understand the utility of operationally seamless Phase II/III design for instantaneous transition of the drug from Phase II to Phase III.

Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance

Drug delivery technologies provide commercial opportunities for pharmaceutical companies by improving the chances of success for a drug development project. They enable the formulation of a promising molecule that might have poor solubility or require selective delivery to a particular tissue, such as the brain. Similarly, drug delivery technologies may enable companies to differentiate products within crowded therapeutic areas, facilitate life cycle management for existing drugs, and reposition existing drugs – proprietary or generic – in new indications where the needs of the patient population are different or, again, where more targeted delivery is required. Products that are reformulated with novel drug delivery systems do not meet the traditional criteria for innovative products – in other words, products that include new active moieties. Nevertheless, GBI Research’s analysis shows that the commercial success of existing products that rely on innovative drug delivery technologies is clear, and these products make significant positive changes for patients.

Scope
  • Detailed analysis of the reasons for the industry to look closely at drug delivery technologies.
  • Exploration of the environment in healthcare and the pharmaceutical industry that is driving companies to invest in drug delivery.
  • Insight into collaborations between the largest pharmaceutical companies and smaller companies with innovative drug delivery technologies.
  • Detailed insight into innovation in drug delivery in key therapeutic areas: oncology, vaccines, diabetes, rheumatology and respiratory diseases.
  • Case studies of leading companies, their technologies and clinical data emerging from important drug development programs.
Reasons to buy
  • Identify leading drug delivery companies.
  • Learn about mergers, acquisitions and collaborations in drug delivery.
  • Develop strategies and priorities for investing in drug delivery technologies.
  • Understand the most important technologies and companies involved in developing new drug delivery technologies in key therapeutic areas.
  • Explore the needs of patients in each therapeutic area and the ways in which drug delivery technologies can be used to meet these within drug development pipelines. 

Get your copy of this report @ http://www.reportsnreports.com/reports/192515-innovations-in-drug-delivery-broad-based-proprietary-technology-platforms-to-address-delivery-efficiency-and-improve-patient-compliance.html

Report Details:

Published: September 2012
No. of Pages: 69
Price:Single User License:US$3500 Corporate User License:US$10500







Pharmaceutical Pricing and Reimbursement - Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-Making

The report provides a comprehensive overview of the healthcare system and pricing and reimbursement process in the US, top five countries of Europe (the UK, Germany, France, Spain and Italy), Japan, Australia and China, with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major changes in pharmaceutical pricing and reimbursement in these nations in the recent past and their impact in the near future.

Get a copy of this report @ http://www.reportsnreports.com/reports/187718-pharmaceutical-pricing-and-reimbursement-adoption-of-health-technology-assessments-hta-optimizes-drug-pricing-and-accelerates-reimbursement-decision-making.html

Report Details:

Published: September 2012
No. of Pages: 68
Price:Single User License:US$3500 Corporate User License:US$10500



Pricing and reimbursement issues are geography-specific and mostly depend upon the economic conditions of the country in question. Governments in the different countries of Europe have been adopting various measures to bring uniformity to the prices of pharmaceuticals by introducing measures such as international price referencing, pharmacoeconomic evaluations, value-based pricing, internal price referencing, price capping, risk sharing models, and positive and negative price lists. The Value Based Pricing System (VBPS), which is in the process of being adopted by the UK, will only reimburse drugs that provide value to patients. In addition, there are issues with respect to orphan drugs since there are no specific regulations governing their pricing, and pharmaceutical companies are exploiting patients by aggressively pricing these therapeutics. Pricing and reimbursement affects many players in the economic environment such as political parties, pharmaceutical companies, regulatory authorities, and patients. This report analyzes the impact of pricing and reimbursement issues on the concerned stakeholders. The report provides information on the economic situation of different countries with statistical graphs and graphs that represent the expenditure made by respective governments with respect to GDP. The report also provides information on the different pricing and reimbursement mechanisms that are being used in the current environment.

Scope
A detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems in the US, top five countries of Europe (the UK, Germany, France, Spain and Italy), Japan, Australia and China.
Analysis of the major pricing and reimbursement mechanisms in each country.
Key trends that have emerged from the recent changes brought about in pricing and reimbursement mechanisms.
Possible major challenges brought about by the enactment of changes in the pricing and reimbursement scenes in the countries covered.

Reasons to buy
Build an understanding of the key pricing and reimbursement mechanisms for pharmaceuticals in the key markets of Europe.
Optimize your investment through the identification and understanding of the changes in the regulatory mechanisms for pharmaceuticals in the economies covered.
Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene for the countries covered.